

Session Title: #275: Childhood Cancer Survivorship: Lessons Learned and Future Steps

Session Type: Extended Education Session

Date: Friday, June 4

Location: S504

Time: 1:00 PM - 3:15 PM

- Childhood Cancer Survivorship: Lessons Learned and Future Steps

Kevin C. Oeffinger, MD

- Current guidelines for follow up of the survivors of pediatric cancers. Current new areas of research including issues related to genetic susceptibility to toxicities

Smita Bhatia, MD, MPH

- Long-term psycho-social effects following the treatment of pediatric cancers.

Christopher Recklitis, MPH, PhD

- Discussion of the Childhood Cancer Survivor Study (CCSS)

Leslie L. Robison, PhD

- Discussion of the Childhood Cancer Survivor Study (CCSS)

Gregory T. Armstrong, MD, MSCE

Session Title: #36: Current Challenges for Cellular Therapies

Session Type: Education Session

Date: Friday, June 4

Location: S504

Time: 3:30 PM - 4:45 PM

- When should immunablative therapies be considered in the treatment of pediatric cancer?

John M. Cunningham, MBBS

- Adoptive cellular therapies utilizing gene modified lymphocytes

Laurence Cooper, MD, PhD

- The role of NK cells in transplant and the non-transplant scenario

Wing H. Leung, MD, PhD

Session Title: #48: The Expanding Role of Antibody-based Therapy in Children, Adolescents, and Young Adults with Cancer

Session Type: Education Session

Date: Saturday, June 5

Location: S504

Time: 8:00 AM - 9:15 AM

- Progress in treatment of high-risk neuroblastoma with immunotherapy

Alice L. Yu, MD, PhD

- Update on Immunotherapy Strategies in the Treatment of Lymphomas in children, adolescents and young adults

Mitchell S. Cairo, MD

- The efficacy of epitope-specific IGFR1 antibodies in therapy of pediatric, adolescent and young adult solid tumors

Douglas Yee, MD

Session Title: #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Session Type: Special Session

Date: Saturday, June 5

Location: N Hall B1

Time: 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Daniel D. Von Hoff, MD

Session Title: #118: Germ Cell Tumors in Children, Adolescents, and Young Adults

Session Type: Meet the Professor Session

Date: Saturday, June 5

Location: E451b

Time: 9:45 AM - 11:00 AM

- Germ Cell Tumors in Children, Adolescents, and Young Adults

A. Lindsay Frazier, MD

Session Title: #81: New Treatments for Sarcoma in Children, Adolescents, and Young Adults

Session Type: Education Session

Date: Saturday, June 5

Location: S504

Time: 1:15 PM - 2:30 PM

- Optimal approaches for achieving local control in children, adolescents, and young adults with sarcoma

R. Lor Randall, MD, FACS

- Optimal strategies for controlling metastatic disease in children, adolescents, and young adults with sarcoma

Douglas S. Hawkins, MD

- Treatment of childhood, adolescent, and young adult sarcoma. Where do we go from here?

Stephen X. Skapek, MD

Session Title: #225: Signaling in Pediatric Cancer Comes to the Clinic

Session Type: Clinical Science Symposium

Date: Saturday, June 5

Location: S504

Time: 4:30 PM - 5:45 PM

- Signaling in Pediatric Cancer Comes to the Clinic

Julia Lynne Glade Bender, MD

- #9500-Lexatumumab: Results of a phase I trial in pediatric patients with advanced solid tumors.

Melinda S. Merchant

- #CRA9501-A phase I pharmacokinetic trial of sonic hedgehog (SHH) antagonist GDC-0449 in pediatric patients with recurrent or refractory medulloblastoma: A Pediatric Brain Tumor Consortium study (PBTC 25).

Amar J. Gajjar, MD

- #9502-A phase I trial of MK-0752 in children with recurrent or refractory CNS malignancies: A Pediatric Brain Tumor Consortium study.

Maryam Fouladi, MD

- Discussion: Signaling comes to the clinic

Richard Greg Gorlick, MD

Session Title: #167: Highlights of the Day I including Clinical Trials Participation Awards

Session Type: Highlights of the Day

Date: Sunday, June 6

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day I including Clinical Trials Participation Awards

Everett E. Vokes, MD

- Clinical Trials Participation Awards

Douglas W. Blayney, MD

- Discussion: Lymphoma and Plasma Cell Disorders

Bruce D. Cheson, MD

- Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy

Alan B Sandler, MD

- Discussion: Patient and Survivor Care

Gretchen Genevieve Kimmick, MD

- Discussion: Melanoma/Skin Cancers

F. Stephen Hodi, MD

Session Title: #84: Optimal Treatment for Adolescents and Young Adults with Acute Lymphoblastic Leukemia

Session Type: Education Session

Date: Sunday, June 6

Location: S504

Time: 8:00 AM - 9:15 AM

- New insights into the biological basis of ALL

Charles Grenfell Mullighan, MBBS, MSc, MD

- Treatment options for high-risk pediatric and adolescent ALL

Ching-Hon Pui, MD

- Converging approaches to treating childhood, adolescent and young adult ALL

Stephen Hunger, MD

Session Title: #164: Pediatric Oncology I

- Pediatric Oncology I
Kenan Onel, MD, PhD
- Pediatric Oncology I
Steven G. DuBois, MD
- #9503-Early results from Children's Oncology Group (COG) ARST0431: Intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS).
Brenda Weigel
- #9504-Second-look operation with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma (RMS): A report from the Children's Oncology Group (COG).
David Anthony Rodeberg
- #9505-Prognostic factors of localized extremity rhabdomyosarcomas: The results of a pooled analysis from U.S. and European cooperative groups.

Odile Oberlin
- #9506-Nonmetastatic osteosarcoma of the extremity: Neoadjuvant chemotherapy with methotrexate (MTX), cisplatin (CDP), doxorubicin (ADM) with or without ifosfamide (IFO)-A randomized trial of the Italian Sarcoma Group (ISG/OS-1).
Stefano Ferrari
- Discussion: Pediatric sarcomas: where to now?
Holcombe E. Grier, MD
- #CRA9507-A phase II trial of proton radiotherapy for medulloblastoma: Preliminary results.
Torunn I. Yock
- #9508-Neurocognitive outcomes after proton radiation for pediatric brain tumors.
Margaret B. Pulsifer
- #9509-Cytogenetic and early-response characteristics of adolescents and young adults with acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) study.
Elizabeth A. Raetz
- #9510-Dose-intensified daunorubicin induction and consolidation plus combined modality maintenance therapy for children with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup study C9710.
James Henry Feusner

- #9511-Advanced-stage anaplastic large-cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trial with standard APO (doxorubicin, prednisone, vincristine) versus consolidation with a regimen including vinblastine: A report from the Children's Oncology Group.

Jacqueline M. Kravaka

- Discussion: Bridging the gap in leukemia

James B. Nachman, MD

Session Title: #44: Evaluating the Evidence and Marketing of Pharmacogenomic Tests

Session Type: Education Session

Date: Sunday, June 6

Location: E353

Time: 11:30 AM - 12:45 PM

- Overview of pharmacogenomics: history, development and role in FDA labeling

Howard L. McLeod, PharmD

- Cyp2D6 testing and tamoxifen

Matthew P. Goetz, MD

- Clinical cases in pharmacogenomics

Michael L. Maitland, MD, PhD

Session Title: #143: Plenary Session including Science of Oncology Award and Lecture

Session Type: Plenary Session

Date: Sunday, June 6

Location: N Hall B1

Time: 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture

Douglas W. Blayney, MD

- Plenary Session including Science of Oncology Award and Lecture

Daniel F. Hayes, MD

- Plenary Session including Science of Oncology Award and Lecture

Frank McCormick, PhD, FRS

- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

Robert A Burger

- Discussion

Elizabeth A. Eisenhauer, MD

- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).

Elisabeth A. Quoix

- #3-Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC).

Yung-Jue Bang

- Discussion

Martin J. Edelman, MD

- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

Steven O'Day, MD

- Discussion: Ipilimumab: The light at the end of the tunnel?

Vernon K Sondak, MD

Session Title: #190: Pediatric Oncology

Session Type: Poster Discussion Session

Date: Sunday, June 6

Location: S Hall A2

Time: 2:00 PM - 6:00 PM

- Pediatric Oncology

Rochelle Bagatell, MD

- Pediatric Oncology

Maryam Fouladi, MD

39A #9521-High throughput transcriptome sequencing of pediatric relapsed acute lymphoblastic leukemia (ALL).

Laura E. Hogan

39B #9522-Association of a genetic variant in the *ABCC2* gene with high methotrexate plasma concentrations in pediatric malignancies.

Melanie M. Hagleitner

39F #9523-Biomarkers in the prediction of vincristine metabolism and neuropathy in pediatric acute lymphoblastic leukemia patients.

Amalia S Lehmann, BS

39G #9524-ABC drug transporter gene expression in neuroblastoma.

Samantha Cialfi

39H #9525-Use of loss of function RNA interference screen to evaluate TNK-2 as a factor involved in rhabdomyosarcoma cell growth.

Fernanda Irene Arnaldez

40A #9526-Genetic variants in *MDR1* and *CYP3A5* and vincristine toxicity in children with acute lymphoblastic leukemia.

Dunja Maroeslea W.M. Te Loo

40B #9527-Use of immunoglobulin heavy chain primer pools to assess minimal residual disease/persistent disease (MRD/PD) in children and adolescents with mature B-cell non-Hodgkin lymphoma (B-NHL): A Children's Oncology Group report.

Bruce Shiramizu

40F #9528-Candidate serum biomarkers of doxorubicin-induced cardiotoxicity in pediatric acute lymphoblastic leukemia assessed by nanoparticle-capture mass spectrometry.

Emanuel Petricoin

40G #9529-A pediatric phase I trial and pharmacokinetic study of MLN8237, an oral selective small molecule inhibitor of aurora a kinase: A Children's Oncology Group Phase I Consortium study.

Yael P. Mosse

40H #9530-A pediatric phase I trial and pharmacokinetic study of aflibercept (VEGF Trap): A Children's Oncology Group Phase I Consortium study.

Julie R. Park

41A #9531-A multicenter, first-in-pediatrics phase I study of ridaforolimus (AP23573, MK-8669) in patients (pts) with refractory solid tumors.

Lia Gore

41B #9532-Phase I trial of lestaurtinib for children with refractory neuroblastoma (NB): A New Approach to Neuroblastoma Therapy (NANT) Consortium Study.

Jane E. Minturn

41C #9533-Phase II window of irinotecan plus carboplatin in newly diagnosed patients with rhabdomyosarcoma: Results of Memorial Sloan-Kettering Cancer Center (MSKCC) Protocol IRB 03-099.

Leonard H. Wexler

41D #9534-Cisplatin plus pirarubicin chemotherapy and combination ifomide, etoposide, pirarubicin, and carboplatin chemotherapy for hepatoblastoma.

Eiso Hiyama

41E #9535-Phase II trial of pemetrexed in children with refractory solid tumors: A Children's Oncology Group study.

Anne Benedicta Warwick

41F #9536-Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with stage III/IV (Group B) and BM+/CNS+ (Group C) mature B-NHL: A Children's Oncology Group report.

Mitchell S. Cairo, MD

41G #9537-A phase II study of bortezomib with ifosfamide and vinorelbine in pediatric patients with refractory/recurrent Hodgkin Disease (HD): A Children's Oncology Group (COG) study.

Terzah M. Horton

41H #9538-Predicting an optimal strategy for insulin-like growth factor 1 (IGF1) signaling interference in Ewing's sarcoma (ES).

Addy C. M. van de Luitgaarden

- Discussion: New agents or combinations in childhood cancers

Frank M. Balis, MD

42A #9539-A pilot study using carboplatin, vincristine and temozolomide for children with progressive/symptomatic low-grade glioma: A Children's Oncology Group (COG) study.

Murali M. Chintagumpala

42B #9540-Phase I study of single-agent perifosine for recurrent pediatric solid tumors.

Oren J Becher

42C #9541-Phase II study of temsirolimus in children with high-grade glioma, neuroblastoma, and rhabdomyosarcoma.

Birgit Geoerger

42D #9542-Hypothalamic/pituitary radiation exposure in low doses on fertility in female childhood cancer survivor study (CCSS) participants.

Daniel M. Green

- Discussion: Advances in CNS therapy

Mark W. Kieran, MD, PhD

Session Title: #211: Pediatric Oncology

Session Type: General Poster Session

Date: Sunday, June 6

Location: S Hall A2

Time: 2:00 PM - 6:00 PM

43A #9543-Phase I trial of oxaliplatin and doxorubicin in children and adolescents with recurrent solid tumors.

Leo Mascarenhas

43B #9544-A phase I trial of continuous hyperthermic peritoneal perfusion using cisplatin in pediatric patients with carcinomatosis.

Andrea Anita Hayes-Jordan

43C #9545-Pilot study of the novel chemotherapy regimen of topotecan, ifosfamide, and carboplatin (TIC) in children with refractory/recurrent solid tumors.

Alice Lee

43D #9546-Dose-finding study by continuous reassessment method (CRM) for topotecan (TT) in combination with ifosfamide (IF) as a second-line therapy for pediatric solid cancer: Preliminary report of phase I/II study.

Hiroshi Kawamoto

43E #9547-An investigator-initiated registration-directed phase I/II clinical trial of irinotecan hydrochloride for refractory pediatric solid tumors.

Atsushi Makimoto

43F #9548-Simulations of cilengitide PK profiles in pediatric population by means of allometric scaling: Reliability and support to BSA-based dose adjustment strategy.

Michael Zuehlendorf

43G #9549-Intensity-modulated radiation therapy for pediatric head and neck rhabdomyosarcoma: French preliminary results.

Julie Leseur

43H #9550-Sorafenib, gamma-secretase inhibitor, and bortezomib as potential therapeutic agents for hepatoblastoma.

Patricia C Sanchez-Diaz

44A #9551-Late side effects of neoadjuvant chemotherapy in patients treated for osteosarcoma and Ewing's sarcoma: An Italian Sarcoma Group study.

Alessandra Longhi

44B #9552-Feasibility of bevacizumab (NSC 704865, BB-IND# 7921) combined with vincristine, topotecan, and cyclophosphamide in patients with

44C #9553-Long-term results of expandable endoprosthesis replacement in children with malignant bone tumors.

Wojciech Woźniak

44D #9554-Long-term neurocognitive outcomes in adult survivors of childhood medulloblastoma.

Kim Edelstein

44E #9555-Premature deaths and severe morbidity in 192 long-term survivors of pediatric optic pathway tumors (OPT): A 50-year study.

Emilie De Carli

44F #9556-Medulloblastoma histological variants as the most powerful prognostic indicator: A 10-year mono-institutional experience.

Maura Massimino

44H #9558-Improved collaboration and clinical trial enrollment in adolescent and young adult (AYA) oncology patients after the establishment of an AYA program.

Peter H Shaw

45A #9559-Survival by race among children with extracranial solid malignancies.

Kelsey Johnson

45B #9560-Physician preferences and knowledge gaps regarding the care of childhood cancer survivors: A survey of ASCO oncologists.

Mackenzie Kigin

45C #9561-Allogeneic stem cell transplantation from HLA identical donor in high risk sarcoma

Franca Fagioli

45D #9562-Reduced intensity conditioning regimen and allogeneic stem cell transplantation from related or unrelated HLA identical donor in high risk neuroblastoma.

Arcangelo Prete

45E #9563-Tandem stem cell transplantation as consolidation therapy for high risk neuroblastoma: The Children's Healthcare of Atlanta experience.

Muna Qayed

45F #9564-STAT3 as a molecular target in pediatric t-cell leukemia.

Jixin Ding

45G #9565-Activity of the heat shock protein 90 (HSP90) inhibitor, SNX-2112, in pediatric cancer cell lines.

Danielle C. Chinn

45H #9566-Effect of bortezomib on ER stress and killing of cisplatin-resistant U2OS osteosarcoma cell line.

Wei-hong Zhao

46A #9567-Modulation of MET with the small molecule inhibitor PF-04217903 might result in decreased osteosarcoma metastasis in vivo.

Lisa M Niswander

46B #9568-GD2 expression in tumorspheres from neuroblastoma cell lines and in tumor-initiating cells derived from patient samples.

Adrienne Marie Hammill

46C #9569-Effect of all-trans retinoic acid on proliferation of human rhabdomyosarcoma and remission in an in vivo mouse xenograft model.

Raya Hamad Saab

46E #9571-Plasma fractionated total metanephrines for biochemical diagnosis of neuroblastoma.

Laura Crosazzo Francini

46F #9572-A prospective trial of prophylaxis and treatment (P+T) of acute tumor lysis syndrome (ATLS) with rasburicase (R) and nonalkaline hydration in children and adolescents (C+A) with intermediate- (Group B) and high-risk (Group C) mature B-NHL: A Children's Oncology Group report.

Stanton Goldman

46G #9573-High-dose methotrexate in the treatment of acute lymphoblastic leukemia: Toxicity profile and comparison of tolerability between two dosage schedules.

Arun Rajagopal Warriar

46H #9574-T-cell lymphoblastic lymphoma in children and adolescents: The experience of the Israel Society of Pediatric Hematology Oncology.

Myriam Weyl Ben Arush

47A #9575-Risk-based outcome of childhood AML: Experience of National Guard Hospital, Jeddah, Saudi Arabia.

Wasil A Jastaniah

47B #9576-High frequency of Gilbert's syndrome in ETV6/RUNX1-positive childhood acute lymphoblastic leukemia (ALL): Implications for etiology.

Yaddanapudi Ravindranath

47C #9577-*Clostridium difficile* infection among children with cancer.

Eric Tai

47D #9578-Iterative anesthesia for radiation therapy in pediatric oncology: Safety of a procedure using propofol alone.

Henri Sebban

47E #9579-Diagnosis of invasive fungal infections by RQ-PCR assay in pediatric acute leukemia induction.

Sushil Mandhaniya

47F #9580-Clinical pharmacokinetics (PK) and safety of high-dose (HD) methotrexate (MTX) during induction therapy of pediatric patients younger than 3 years of age with primary brain tumors.

Trevor McKibbin

47G #9581-Criteria defining the duration of chemoreduction with focal treatment in retinoblastoma: A retrospective analysis.

Maja Beck Popovic

Session Title: #257: Pediatric Oncology

Session Type: Poster Discussion Session

Date: Sunday, June 6

Location: S504

Time: 5:00 PM - 6:00 PM

- Pediatric Oncology

Rochelle Bagatell, MD

- Pediatric Oncology

Maryam Fouladi, MD

39A #9521-High throughput transcriptome sequencing of pediatric relapsed acute lymphoblastic leukemia (ALL).

Laura E. Hogan

39B #9522-Association of a genetic variant in the *ABCC2* gene with high methotrexate plasma concentrations in pediatric malignancies.

Melanie M. Hagleitner

39F #9523-Biomarkers in the prediction of vincristine metabolism and neuropathy in pediatric acute lymphoblastic leukemia patients.

Amalia S Lehmann, BS

39G #9524-ABC drug transporter gene expression in neuroblastoma.

Samantha Cialfi

39H #9525-Use of loss of function RNA interference screen to evaluate TNK-2 as a factor involved in rhabdomyosarcoma cell growth.

Fernanda Irene Arnaldez

40A #9526-Genetic variants in *MDR1* and *CYP3A5* and vincristine toxicity in children with acute lymphoblastic leukemia.

Dunja Maroeslea W.M. Te Loo

40B #9527-Use of immunoglobulin heavy chain primer pools to assess minimal residual disease/persistent disease (MRD/PD) in children and adolescents with mature B-cell non-Hodgkin lymphoma (B-NHL): A Children's Oncology Group report.

Bruce Shiramizu

40F #9528-Candidate serum biomarkers of doxorubicin-induced cardiotoxicity in pediatric acute lymphoblastic leukemia assessed by nanoparticle-capture mass spectrometry.

Emanuel Petricoin

40G #9529-A pediatric phase I trial and pharmacokinetic study of MLN8237, an oral selective small molecule inhibitor of aurora a kinase: A Children's Oncology Group Phase I Consortium study.

Yael P. Mosse

40H #9530-A pediatric phase I trial and pharmacokinetic study of aflibercept (VEGF Trap): A Children's Oncology Group Phase I Consortium study.

Julie R. Park

41A #9531-A multicenter, first-in-pediatrics phase I study of ridaforolimus (AP23573, MK-8669) in patients (pts) with refractory solid tumors.

Lia Gore

41B #9532-Phase I trial of lestaurtinib for children with refractory neuroblastoma (NB): A New Approach to Neuroblastoma Therapy (NANT) Consortium Study.

Jane E. Minturn

41C #9533-Phase II window of irinotecan plus carboplatin in newly diagnosed patients with rhabdomyosarcoma: Results of Memorial Sloan-Kettering Cancer Center (MSKCC) Protocol IRB 03-099.

Leonard H. Wexler

41D #9534-Cisplatin plus pirarubicin chemotherapy and combination ifomide, etoposide, pirarubicin, and carboplatin chemotherapy for hepatoblastoma.

Eiso Hiyama

41E #9535-Phase II trial of pemetrexed in children with refractory solid tumors: A Children's Oncology Group study.

Anne Benedicta Warwick

41F #9536-Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with stage III/IV (Group B) and BM+/CNS+ (Group C) mature B-NHL: A Children's Oncology Group report.

Mitchell S. Cairo, MD

41G #9537-A phase II study of bortezomib with ifosfamide and vinorelbine in pediatric patients with refractory/recurrent Hodgkin Disease (HD): A Children's Oncology Group (COG) study.

Terzah M. Horton

41H #9538-Predicting an optimal strategy for insulin-like growth factor 1 (IGF1) signaling interference in Ewing's sarcoma (ES).

Addy C. M. van de Luitgaarden

- Discussion: New agents or combinations in childhood cancers

Frank M. Balis, MD

42A #9539-A pilot study using carboplatin, vincristine and temozolomide for children with progressive/symptomatic low-grade glioma: A Children's Oncology Group (COG) study.

Murali M. Chintagumpala

42B #9540-Phase I study of single-agent perifosine for recurrent pediatric solid tumors.

Oren J Becher

42C #9541-Phase II study of temsirolimus in children with high-grade glioma, neuroblastoma, and rhabdomyosarcoma.

Birgit Geoerger

42D #9542-Hypothalamic/pituitary radiation exposure in low doses on fertility in female childhood cancer survivor study (CCSS) participants.

Daniel M. Green

- Discussion: Advances in CNS therapy

Mark W. Kieran, MD, PhD

Session Title: #168: Highlights of the Day II including Partners in Progress Award

Session Type: Highlights of the Day

Date: Monday, June 7

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award

Douglas W. Blayney, MD

- Highlights of the Day II including Partners in Progress Award

Kim Allyson Margolin, MD

- Partners in Progress Award Recipient
Ellen V. Sigal, PhD
 - Discussion: Genitourinary (Prostate) Cancer
Nicholas J. Vogelzang, MD
 - Discussion: Gastrointestinal (Colorectal) Cancer
Howard S. Hochster, MD
 - Discussion: Gynecologic Cancer
Claire F. Verschraegen, MD
 - Discussion: Myeloma
Jean L. Harousseau, MD
 - Discussion: Cancer Prevention/Epidemiology
Scott Michael Lippman, MD
-

Session Title: #97: The Biology and Treatment of Wilms Tumor

Session Type: Education Session

Date: Monday, June 7

Location: S504

Time: 8:00 AM - 9:15 AM

- Wilms Tumor: Unsettled questions and controversies
Jeffrey Dome, MD
- New developments in Wilm tumor genetics
Nazneen Rahman, PhD, FRCP
- Gene Expression Arrays: What have they taught us about Wilms tumor?

Elizabeth Perlman, MD

Session Title: #106: Translocation-specific Sarcomas: Can Molecular Targets Translate to Therapeutics?

Session Type: Education Session

Date: Monday, June 7

Location: S406 (Vista Room)

Time: 8:00 AM - 9:15 AM

- Target genes of chimeric transcription factors in pediatric sarcomas: a source of potential therapeutic targets

Marc Ladanyi, MD

- Targeting protein products of sarcoma specific translocations with small molecules

Jeffrey Toretsky, MD

- IGF1R targeting of translocation-associated sarcomas

Lee J. Helman, MD

Session Title: #165: Pediatric Oncology II

Session Type: Oral Abstract Session

Date: Monday, June 7

Location: S504

Time: 9:30 AM - 12:30 PM

- Pediatric Oncology II

Tara O. Henderson, MD, MPH

- Pediatric Oncology II

Gregory T. Armstrong, MD, MSCE

- #9512-Anthracycline-related cardiomyopathy in childhood cancer survivors and association with polymorphisms in the carbonyl reductase genes: A Children's Oncology Group study.

Javier G. Blanco

- #9513-Late cardiac status in long-term survivors of childhood high-risk ALL 8 years after continuous or bolus infusion of doxorubicin: The DFCI Childhood ALL 91-01 randomized trial.

Steven Lipshultz

- #9514-Chronic medical conditions, health status, and health care practices at 25 years in 5-year survivors of Wilms tumor: A report from the Childhood Cancer Survivor Study.

Amanda M. Termuhlen

- Discussion: Cardiac status in survivors of pediatric cancer

Melissa M. Hudson, MD

- #9515-Childhood cancer: Do females experience more acute toxicities than males? A Report from the Children's Oncology Group

Kathleen Ann Meeske

- #9516-MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study.

Gregory A Yanik

- #9517-Racial and ethnic disparities in disease presentation and survival among children with neuroblastoma (NBL): A Children's Oncology Group (COG) study.

Susan Lerner Cohn, MD

- #9518-Clinical and biological features predictive of survival after relapse of neuroblastoma: A study from the International Neuroblastoma (NB) Risk Group (INRG) Database.

Wendy B. London, PhD

- Discussion: Prognostic Variables in Neuroblastoma

Andrew Pearson, MD, FRCP

- #9519-Multiple subsequent neoplasms in the childhood cancer survivor study (CCSS) cohort.

Gregory T. Armstrong, MD, MSCE

- #9520-Gastrointestinal malignancies as a subsequent malignant neoplasm in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.

Tara O. Henderson, MD, MPH

- Discussion

Flora E. Van Leeuwen, PhD

Session Title: #91: Response-based Therapy: A Personalized Approach to Pediatric Hodgkin Lymphoma

Session Type: Education Session

Date: Monday, June 7

Location: S504

Time: 1:15 PM - 2:30 PM

- Optimizing Chemotherapy: Response and Biology

Cindy L. Schwartz, MD

- RT or not RT, that is the question!

Louis S. Constine, MD

- Functional Imaging and Hodgkin Lymphoma

Stephan Voss, MD, PhD

Session Title: #22: Caring for the Child with Brain Cancer

Session Type: Education Session

Date: Monday, June 7

Location: S504

Time: 3:00 PM - 4:15 PM

- High Dose Chemotherapy for Malignant Brain Tumors- What have we learned in the past 2 decades and what does the future hold for this therapy

Amar J. Gajjar, MD

- Relapsed Pediatric CNS tumors in 2010 □ strategies and new agents

Stewart Goldman, MD

- Understanding Late Effects of Irradiation and Measures to Reduce Dose to Normal Tissue

Thomas E. Merchant, DO, PhD

Session Title: #15: Biology and Treatment of Breast Cancer in Survivors of Pediatric Cancer

Session Type: Education Session

Date: Monday, June 7

Location: S504

Time: 4:45 PM - 6:00 PM

- Overview of breast cancers incidence in pediatric cancer survivors with a focus on education and screening

Tara O. Henderson, MD, MPH

- Update on the genetics of pediatric survivors who develop breast cancer and tumor biology

Gail E. Tomlinson, MD, PhD

- Use of tamoxifen in Hodgkin's patients for the prevention of breast cancer

Melanie R. Palomares, MD

Session Title: #38: Decision-making Capacity: When Should Oncologists Honor Refusals of Treatment by Individuals with Diminished Capacity?

Session Type: Education Session

Date: Monday, June 7

Location: S100b

Time: 4:45 PM - 6:00 PM

- Cancer patients with diminished capacity: ethical dilemmas and strategies for resolving them

Rebecca D. Pentz, PhD

- Lessons from Pediatrics

Steven Joffe, MD, MPH

Session Title: #169: Highlights of the Day III

Session Type: Highlights of the Day

Date: Tuesday, June 8

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day III

Kathy Miller, MD

- Discussion: Breast Cancer - Local/Regional and Adjuvant Therapy

Kathy Miller, MD

- Discussion: Lung Cancer - Metastatic

Charles M. Rudin, MD, PhD

- Discussion: Sarcoma

Gary K. Schwartz, MD

- Discussion: Gastrointestinal (Noncolorectal) Cancer

C. D. Blanke, MD

- Discussion: Head and Neck Cancer

Everett E. Vokes, MD